Related Experiment Video
Updated: Apr 20, 2026
10:58
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
13.6K
Glioblastoma multiforme classified as mesenchymal subtype.
Ilian G Koev1, Yana N Feodorova2, Maria H Kazakova2
1Clinic of Neurosurgery, St. George University Hospital, Plovdiv
Folia Medica
|December 2, 2014
Summary
This study reports a glioblastoma multiforme case with poor survival, identifying high levels of TNF-α, CD44, YKL-40, and IL-6 as unfavorable prognostic markers. These findings suggest a mesenchymal subtype associated with rapid progression.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Immunology
Background:
- Glioblastoma multiforme (GBM) prognosis is influenced by clinical, cellular, genetic, and immunological factors.
- Identifying adverse prognostic markers is crucial for understanding GBM heterogeneity and patient outcomes.
Observation:
- A case of a 71-year-old man with histologically verified glioblastoma multiforme and a short postoperative survival of 48 days is presented.
- The patient did not receive radiotherapy or adjuvant temozolomide due to rapid disease progression.
Findings:
- Molecular and immunological analyses revealed very high transcription levels of CD44, YKL-40, and IL-6 genes.
- Increased gene expression of Tumor Necrosis Factor-alpha (TNF-α) and elevated serum concentrations of TNF-α, YKL-40, and IL-6 were observed.
- A reduced serum concentration of CD44 was noted in this patient.
Implications:
- High expression levels of TNF-α, CD44, YKL-40, and IL-6 suggest the tumor belongs to the mesenchymal subtype of GBM.
- This subtype is associated with a rapid clinical course and a poor prognosis.
- These markers may aid in categorizing GBM subtypes and predicting patient survival.
